Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

H. Borghaei, L. Paz-Ares, L. Horn, D. R. Spigel, M. Steins, N. E. Ready, L. Q. Chow, E. E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhufl, O. Arrieta, M. A. Burgio, J. Fayette, H. Lena, E. Poddubskaya, D. E. Gerber, S. N. Gettinger, C. M. RudinN. Rizvi, L. Crina, G. R. Blumenschein, S. J. Antonia, C. Dorange, C. T. Harbison, F. Graf Finckenstein, J. R. Brahmer

Research output: Contribution to journalArticlepeer-review

7569 Scopus citations

Fingerprint

Dive into the research topics of 'Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences